NYSE · Healthcare
BRISTOL MYERS SQUIBB CO (BMY)
As-reported financials and recent SEC filings for BRISTOL MYERS SQUIBB CO, latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$48.19B
Net income
$7.05B
Net margin
14.6%
Diluted EPS
$3.46
ROE
38.1%
P/E (TTM)
16.0×
Market cap
$116.66B
Debt / equity
2.3×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $48.19B | $48.30B | $45.01B | $46.16B | $46.38B |
| Gross profit | $34.26B | $34.33B | $34.31B | $36.02B | $36.45B |
| Operating income | — | — | — | — | — |
| Net income | $7.05B | $-8.95B | $8.03B | $6.33B | $6.99B |
| Diluted EPS | $3.46 | $-4.41 | $3.86 | $2.95 | $3.12 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-06-05
View on EDGAR →11-K2026-06-05
View on EDGAR →11-K2026-06-05
View on EDGAR →11-K2026-06-05
View on EDGAR →S-82026-05-08
View on EDGAR →8-K2026-05-08
View on EDGAR →42026-05-05
View on EDGAR →10-Q2026-04-30
View on EDGAR →Go deeper on BMY
Search BRISTOL MYERS SQUIBB CO’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.